Bellerophon Therapeutics, a maker of medtech to treat heart attacks and hypertension, files for an IPO worth as much as $69 million.
A New Jersey company developing a liquid bioabsorbable device to treat heart attacks filed plans for an initial public offering worth up to $69 million.
Bellerophon Therapeutics said it envisions trading on the NASDAQ exchange under the symbol "BLPH," according to a regulatory filing detailing its proposed flotation. Per-share pricing terms weren't disclosed.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1AZqeEO
Cap comentari:
Publica un comentari a l'entrada